Article
Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance.
Clinical pharmacology and therapeutics - 1 Apr 2014
Werk A N, Lefeldt S, Bruckmueller H, Hemmrich-Stanisak G, Franke A, Roos M, Küchle C, Steubl D, Schmaderer C, Bräsen J H, Heemann U, Cascorbi I, Renders L
Abstract excerpt
Cytochrome P450 3A4 (CYP3A4) is a major drug-metabolizing enzyme that is widely investigated. So far, no homozygous inactive variant has been described. We report on a 19-year-old kidney transplant patient suffering from Alport syndrome, who experienced unexpected high tacrolimus plasma trough levels during immunosuppressant therapy. Because nonadherence, liver failure, or drug-drug interactions could be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.